Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Tianjin TEDA Biomedical Engineering Co was 14.50. The lowest was 2.48. And the median was 4.35.
HKSE:08189's Price-to-Net-Current-Asset-Value is not ranked *
in the Agriculture industry.
Industry Median: 3.815 * Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
Tianjin TEDA Biomedical Engineering Co (HKSE:08189) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Tianjin TEDA Biomedical Engineering Co Net Current Asset Value Related Terms
Tianjin TEDA Biomedical Engineering Co Net Current Asset Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tianjin TEDA Biomedical Engineering Co Net Current Asset Value Chart
Tianjin TEDA Biomedical Engineering Co Annual Data
HKSE:08189 vs CTVA, CF, MOS: Net Current Asset Value Comparison
For the Agricultural Inputs subindustry, Tianjin TEDA Biomedical Engineering Co's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tianjin TEDA Biomedical Engineering Co Price-to-Net-Current-Asset-Value vs Agriculture Industry
For the Agriculture industry and Basic Materials sector, Tianjin TEDA Biomedical Engineering Co's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Tianjin TEDA Biomedical Engineering Co's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of HK$-0.03 mean?
Tianjin TEDA Biomedical Engineering Co (HKSE:08189) has a Net Current Asset Value of HK$-0.03 as of Dec. 2025. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Tianjin TEDA Biomedical Engineering Co and its competitors. According to the industry distribution chart, Tianjin TEDA Biomedical Engineering Co ranks #999999 out of 162 companies in the Agriculture industry.
Is Tianjin TEDA Biomedical Engineering Co's Net Current Asset Value too high?
Tianjin TEDA Biomedical Engineering Co's current Net Current Asset Value is HK$-0.03. Based on the distribution chart, Tianjin TEDA Biomedical Engineering Co ranks #999999 out of 162 companies in the Agriculture industry, which is in the bottom quartile relative to peers. Overall, Tianjin TEDA Biomedical Engineering Co has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tianjin TEDA Biomedical Engineering Co's Net Current Asset Value compare to CTVA and CF?
According to the Agriculture industry distribution chart, Tianjin TEDA Biomedical Engineering Co ranks #999999 out of 162 companies for Net Current Asset Value. This places Tianjin TEDA Biomedical Engineering Co in the lower half of its industry. The industry median Net Current Asset Value is 3.82. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for an Agriculture company?
The median Net Current Asset Value among Agriculture companies is 3.82, based on 162 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Tianjin TEDA Biomedical Engineering Co and its competitors. For the Agriculture industry, the median Net Current Asset Value is 3.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tianjin TEDA Biomedical Engineering Co's current Net Current Asset Value is HK$-0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tianjin TEDA Biomedical Engineering Co stock overvalued right now?
Based on GuruFocus' analysis, Tianjin TEDA Biomedical Engineering Co (HKSE:08189) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.19, compared to a current price of HK$0.26 — trading 34.2% above its estimated fair value. The current Net Current Asset Value is HK$-0.03. Tianjin TEDA Biomedical Engineering Co's overall GF Score™ is 28/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Tianjin TEDA Biomedical Engineering Co (HKSE:08189), the current Net Current Asset Value is HK$-0.03 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tianjin TEDA Biomedical Engineering Co (HKSE:08189) Overvalued in 2026?
Based on GuruFocus' analysis, Tianjin TEDA Biomedical Engineering Co stock appears to be overvalued.
The current stock price of HK$0.26 is trading 34.2% above its estimated GF Value™ of HK$0.19.
GuruFocus considers Tianjin TEDA Biomedical Engineering Co to be Significantly Overvalued.
Key valuation signals for HKSE:08189:
Net Current Asset Value: HK$-0.03
GF Value™: HK$0.19 vs. price of HK$0.26 (34.2% above fair value)
No single metric tells the full story. See the HKSE:08189 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tianjin TEDA Biomedical Engineering Co Ltd principally engages in manufacture and sale of biological compound fertiliser products and elderly care and health care services and related products. The group is principally engaged in manufacturing and selling biological compound fertilisers, AI health & elderly care products and services. It operates in two segments namely; fertilisers products; and AI health & elderly care products and services. The company generates a majority of its revenue from the Fertilisers products segment. The People's Republic of China is the primary geographical market for the company.
28GF Score
Get the complete analysis for HKSE:08189
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08189 has been successfully added to your 
